beta-Endorphin omission analogs: dissociation of immunoreactivity from other biological activities.

AUTOR(ES)

Li, C H

RESUMO

An analog of human beta-endorphine with omission of four residues at positions 11, 14, 20, and 22 has been synthesized. This analog and other synthetic analogs with deletion of a single amino acid at position 2, 5, 6, 10, 11, 12, 13, 15, or 22 have been assayed for analgesic potency, ileal opiate activity,opiate receptor-binding activity, andimmunoreactivity. Results show that deletion of a single amino acid of the beta-endorphin molecule outside of the enkephalin segment to give des-Gln11-, des-Thr12, des-Pro13-, des-Leu14-, des-Val15-, des-Asn20-, or des-Ile22-beta-endorphin markedly reduced or abolished the immunoreactivity yet gave substantial retention of opiate potencies. Deletion of a single amino acid of beta-endorphin within the enkephalin segment (des-Gly3- or des-Met5-beta-endorphin) did not markedly affect the immunoactivity; however, the opiate activities were abolished or markedly reduced. The data indicate a clear dissociation of immunoactivity from analgesic, ileal-opiate, and opiate receptor-binding activities.

Documentos Relacionados

• Distribution of beta-endorphin immunoreactivity in normal human pituitary.
• beta-endorphin-(1-27) is an antagonist of beta-endorphin analgesia.
• Regional dissociation of beta-endorphin and enkephalin contents in rat brain and pituitary.
• beta-Endorphin enhances lymphocyte proliferative responses.
• beta-Endorphin induces nonconvulsive limbic seizures.